Aurobindo Pharma China Facility Targets Break-Even by FY26
Aurobindo Pharma's China facility currently faces $1M loss but aims for break-even by Q3-Q4 FY26. CFO outlines growth drivers including Pen-G ramp-up and biosimilar commercialization.
Aurobindo Pharma's China facility currently faces $1M loss but aims for break-even by Q3-Q4 FY26. CFO outlines growth drivers including Pen-G ramp-up and biosimilar commercialization.
Karnataka Health Minister Dinesh Gundu Rao urges the pharma sector to adhere to regulations, highlighting critical public health and industry credibility issues.
India's new labour reforms promise better worker protection and industry growth. Learn how these changes will transform employment landscape and boost economic development.
Eli Lilly makes pharmaceutical history as first company to achieve $1 trillion market capitalization after shares rose 1.7% on November 21, 2025. Learn what this means for investors.
A smallcap pharma stock listed on NSE defied market trends with a 10% surge on November 21, 2024. Discover the driving factors behind this remarkable performance.
India's IPO market surges with ₹76,000 crore offerings. Excelsoft Technologies fully subscribed, Sudeep Pharma at 50%. Expert analysis on both IPOs and GMP trends revealed.
CII's National Pet Food Summit urges FSSAI to establish dedicated regulations and evidence-based nutrition standards for India's growing pet food industry. Join the movement for safer pet nutrition.
Sudeep Pharma's ₹895 crore IPO opens with ₹563-593 price band. Grey market shows ₹130 premium. Analysts recommend long-term investment for 2-5 years horizon.
Sudeep Pharma's ₹895 crore IPO opens today. Price band ₹563-593 per share. Learn about company details, investment minimums & global presence. Subscribe now!
Sudeep Pharma's ₹95 crore IPO opens November 21 with strong grey market premium. Learn price band, dates, financials & investment details for this pharma ingredients maker.
Sudeep Pharma's ₹895 crore IPO opens November 21-25. Price band ₹563-593 per share. Company manufactures pharmaceutical excipients and speciality ingredients.
Sudeep Pharma IPO opens November 21 with price band ₹563-593 per share. Company aims to raise ₹95 crore. Learn key dates, financials, and investment details.
Remedium Lifecare reports stellar Q2 results with profit nearly doubling to ₹38.62 crore. Revenue surges 22% driven by strong pharmaceutical exports and domestic growth.
European weight-loss drug makers surge as investors rotate capital from expensive AI stocks into healthcare. Zealand Pharma leads with a 20% weekly jump. Explore the market dynamics.
Purdue Pharma receives court approval for $7.4 billion opioid settlement after Supreme Court intervention. Sackler family to pay $6.5 billion over 15 years in landmark case.
Federal judge approves Purdue Pharma's bankruptcy plan requiring Sackler family to pay $7 billion and surrender company ownership. Thousands of opioid victims to receive compensation in historic settlement.
Lincoln Pharmaceuticals Ltd announces ambitious plan to achieve Rs 1000 crore revenue within three years through strategic expansion and new product launches. Read more about their growth strategy.
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Tragic boiler explosion at pharmaceutical factory in Gujarat's Bharuch district claims 2 lives, leaves 20 injured. Massive fire brought under control by emergency teams.
India's DCGI orders nationwide inspections of small pharma units as WHO flags toxic cough syrups. MSMEs struggle to meet new Schedule M compliance deadline of January 2026.
DCGI directs state authorities to enforce strict GMP compliance by December 31, 2025. Delhi, Himachal Pradesh, Uttarakhand already taking action against non-compliant manufacturers.
India's drug regulator DCGI mandates global manufacturing standards for all pharma companies by January 2026. State regulators ordered to begin inspections immediately. Read about the strict compliance requirements.
Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.
Indian pharmaceutical companies are reporting exceptional earnings driven by US generic drug sales, leading to major fundraising initiatives for expansion into medtech and wellness sectors.
British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.
Maruti Suzuki, Tata, and Mahindra debate new emission norms as government proposes stricter fuel efficiency standards. Discover how this battle could reshape India's auto industry and affect vehicle prices.
Solara Active Pharma Sciences faces challenging quarter with ₹10 crore net loss despite revenue growth. Discover the operational challenges and management's recovery strategy.
India's pharmaceutical giant Sun Pharma reports steady Q2 growth with 9% revenue increase while navigating US market challenges. Key insights from their latest earnings report.
Discover why Navin Fluorine International shares skyrocketed 22% in just three trading sessions. Expert analysis reveals the key drivers behind this chemical sector powerhouse's impressive rally and what investors should watch next.